Mitsui Chemicals, Inc. has signed an agreement to acquire JSR Corp., a Tokyo-based developer and manufacturer of semiconductor materials including photoresists, from investment funds managed by JIC Capital, Ltd. The transaction is valued at ¥1.84 trillion ($11.6 billion) including debt and would make JSR a consolidated subsidiary of Mitsui Chemicals.
Mitsui Chemicals will buy all JSR common shares held by JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership, jointly with Development Bank of Japan Inc. (DBJ), which will invest ¥200 billion ($1.3 billion). The price consists of ¥1.3921 trillion ($8.8 billion) in equity value and ¥447.9 billion ($2.8 billion) in interest-bearing debt and other items, with the final consideration subject to adjustment at closing. Mitsui also expects to acquire JSR’s Class A and Class B preferred shares from Mizuho Bank and DBJ for cash. Those shares are to convert to common shares after closing, while DBJ’s common shares will convert to non-voting preferred shares.
The acquisition is intended to support Mitsui Chemicals’ “VISION 2030” plan, which combines a specialty chemicals pillar—Life & Healthcare Solutions, Mobility Solutions and ICT Solutions—with a Basic & Green Materials (B&GM) pillar centered on petrochemicals. Mitsui said JSR’s advanced photoresists, customer base in semiconductor and optical fields, and global reach make it a core part of its ICT Solutions business. In front-end processes, the company plans to combine its MITSUI PELLICLE products with JSR’s advanced photoresists; in back-end processes, it plans to pair its ICROS Tape with JSR’s thick-film resists. Mitsui is targeting about ¥40 billion ($253 million) in annual incremental profit by fiscal 2035 from growth and cost synergies.
Mitsui Chemicals also widened the scope of a planned split-off of its B&GM business, first announced as under consideration in May 2025, to include its Mobility Solutions business. The aim is to form a polymer science company with an integrated polymer chain spanning upstream petrochemicals and downstream functional polymers. Mitsui also plans to become more asset-light in underperforming businesses, improve its cash conversion cycle and sell shareholdings. Including JSR’s review of its non-core life sciences business, which covers contract research and contract development and manufacturing, Mitsui expects benefits representing business value of ¥350 billion ($2.2 billion) or more.
Funding is to come from a ¥1.64 trillion ($10.4 billion) bridge loan from Mitsui’s principal financial institutions and DBJ’s ¥200 billion investment. Net debt/EBITDA is expected to temporarily exceed 4x after closing. To protect an “A”-category credit rating, Mitsui plans to refinance the bridge loan within one year using bank loans, bonds and equity. It aims to have the equivalent of ¥300 billion ($1.9 billion) recognized as equity by rating agencies, cap common share issuance including treasury shares at ¥150 billion ($948 million), and add ¥300 billion of mezzanine financing, half of which is assumed to count as equity.
The company filed a shelf registration on Nov. 9 for up to ¥150 billion of common shares. It becomes effective Nov. 17, 2026, and runs through Nov. 16, 2028; proceeds will go toward partial repayment of the bridge loan. SMBC Nikko Securities and Mizuho Securities are expected to be the primary underwriters.
Four JSR affiliates will become specified subsidiaries of Mitsui Chemicals: Inpria Corp. in Corvallis, Ore.; KBI Biopharma, Inc. in Durham, N.C.; JSR North America Holdings, Inc. in Sunnyvale, Calif.; and JSR Life Sciences, LLC in Sunnyvale. JSR reported revenue of ¥440.7 billion ($2.8 billion), consolidated operating profit of ¥40.5 billion ($256 million) and profit attributable to owners of ¥59.3 billion ($375 million) for the fiscal year ended March 2026.
The transaction is subject to competition-law and foreign-investment approvals in Japan and overseas. Mitsui Chemicals aims to close in the second half of the fiscal year ending March 2028 and expects the impact on results for the fiscal year ending March 2027 to be minor. Currency conversions in the announcement used an exchange rate of ¥158.2 per $1 on Nov. 9, 2026.